Hadassah

Hadassah Collaborates with Columbia University to Identify Treatment for Alopecia

Friday, Jun 5 2015

Working in collaboration with Columbia University, a team of Hadassah Medical Organization physicians have discovered that an arthritis medication may be the solution to baldness caused by alopecia.

The researchers have found that Baricitinib, a medicine in development for treatment of rheumatoid arthritis, may prove effective for severe Alopecia Areata (AA), a common autoimmune disease which causes sudden or gradual hair loss. "Despite its high prevalence," the team reports, "there are no Food and Drug Administration-approved treatments for AA."

The team, including Hadassah Dermatologist Dr. Yuval Ramot, Prof. Abraham Zlotogorski, Director of Hadassah Hospital Ein Kerem's Department of Dermatology and its Hair Loss Clinic, and Prof. Yackov Berkun of Hadassah Hospital Mount Scopus' Pediatric Unit, has found the medicine to be effective in both animals and humans.

"This discovery opens a variety of options for future treatment of AA," notes Dr. Ramot. "That said, extensive clinical trials are still needed in order to fully confirm the findings, before marketing these new medications for treatment of AA."

The research team hopes to begin such clinical trials in the near future. The present study is highlighted in the April 2015 issue of EBioMedicine.

Comments

From: Marjorie on June 6, 2015
I believe I would be a candidate for these clinical trials. Please contact me.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 30 2016

Hadassah Teams Up with Spinal Cord Institute to Study Outcomes of Traumatic Injuries

The medical interventions and outcomes for Israelis with a spinal cord injury (SCI) will now be captured in the Rick Hansen SCI Registry (RHSCIR), thanks to the November 16th launch of a partnership between the Hadassah Medical Organization and the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization named after the paralympic athlete who suffered a severe spinal cord injury following a car accident.

READ MORE ›
alt_text

Thursday, Nov 17 2016

A Birthday Party in Hadassah’s PICU: Helping a Four-Year-Old Recover

Yehoshua "Shuki" Pepper was crossing a Jerusalem street with an older sibling when a car ran him over. He was rushed to Hadassah Hospital Ein Kerem's Pediatric Intensive Care Unit in fair condition, but he wasn't speaking and subsequent MRIs of his head injury were worrisome.

READ MORE ›
alt_text

Thursday, Nov 17 2016

Ethiopian Pre-Nursing Students: On the Way to Fulfilling a Dream

“I know that some people are fine with looking at a screen all day, but I know I need the human touch--to work with people. I want to be a nurse, " relates Sarah Talala, one of the 18 students of Ethiopian background who were given the opportunity to take a course which enabled them to advance to pre-academic studies at the Hebrew University and then on to nursing school at the Hadassah-Hebrew University Henrietta Szold School of Nursing.

READ MORE ›
alt_text

Monday, Nov 14 2016

Granalix BioTechnologies Introduces Food Additive to Protect Against Neurodegenerative Disease

Granalix BioTechnologies, whose founder and Chief Executive Officer is Hadassah Medical Organization Experimental Neurologist Prof. Ruth Gabizon, has launched a food supplement containing pomegranate oil that has proven to protect against neurodegenerative diseases in pre-clinical models.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More